These data suggested that the frequency of CD14−/low/CD16+ monocytes was reduced in fast progressing patients with ALS, and the cell surface expression of CD14 on monocytes was reduced in both fast and slowly progressing patients. This evidence concerns the gene CD14 and amyotrophic lateral sclerosis.